Form 8-K - Current report:
SEC Accession No. 0001437749-23-015914
Filing Date
2023-05-26
Accepted
2023-05-26 07:37:28
Documents
14
Period of Report
2023-05-25
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20230524_8k.htm   iXBRL 8-K 55891
6 moleculin01.jpg GRAPHIC 5391
  Complete submission text file 0001437749-23-015914.txt   204594

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20230525.xsd EX-101.SCH 3601
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20230525_def.xml EX-101.DEF 11532
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20230525_lab.xml EX-101.LAB 15414
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20230525_pre.xml EX-101.PRE 11688
8 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20230524_8k_htm.xml XML 2562
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 23963070
SIC: 2834 Pharmaceutical Preparations